Zevra Therapeutics, Inc.

NASDAQ:ZVRA

Biotechnology

Healthcare
$9.28 +2.44%

+$0.31 today

Market cap
$552.20M
Beta
0.89
P/E (TTM)
6.1
EPS (TTM)
$2.13
52W Low $7.16High $14.27

Volume 0.62M

Average 1.43M

ZVRA Weighted Avg Shares

Average number of basic shares outstanding during the period, used to calculate basic EPS.

Zevra Therapeutics, Inc.NASDAQ: ZVRA

Weighted Avg Shares · Q1 FY2026 · quarter ended Mar 2026

Weighted avg shares grows, but more slowly than its trailing trend

Q1 FY2026 weighted avg shares of 58.41M shares rose 8.0% year over year, behind the +13.7% change in trailing-twelve-month weighted avg shares. Sequentially, it rose 5.6% from the prior quarter. Over 3 fiscal years it compounded at +17.1% a year.

Context

  • Weighted avg shares increased in 3 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly growth recovers from +8.0% toward the trailing-twelve-month pace of +13.7%.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterMar 2026
58.41M+5.6% QoQ
Last fiscal yearDec 2025
55.31M+19.6% YoY
LTMMar 2026
56.11M+13.7% YoY
Weighted Avg Shares past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+8.0%——
1 year+19.6%——
3-year CAGR+17.1%——
5-year CAGR——
10-year CAGR——

Weighted Avg Shares history

Shares · from the income statement

Latest · FY2025
55.31M USD
Year-over-year change
+19.6%
4-year CAGR
+16.8%

Weighted Avg Shares vs competitors

How ZVRA compares with its peers on the latest reported figures

  • ZVRA's LTM Mar 2026 weighted avg shares of 56.11M shares is the 8th highest of the 11 companies compared; the peer median is 62.36M shares.
  • Its year-over-year change of +13.7% is the 4th highest of 11, against a peer median of +4.0%.
  • Over three fiscal years its annual growth of +17.1% compares with a peer median of +2.2%.
ZVRA Competitors Peer median
Weighted Avg Shares for ZVRA and competitors
Company Period LTM YoY 3-year CAGR
NMRANeumora Therapeutics, Inc. Common StockLTM Mar 2026166.7M +4.0%+2.4%
ALKSAlkermes plcLTM Sep 2026166.35M +1.5%+0.2%
NBIXNeurocrine Biosciences, Inc.LTM Sep 2026100.65M +1.1%+1.3%
XENEXenon Pharmaceuticals Inc.LTM Sep 202691.49M +16.1%+9.4%
JAZZJazz Pharmaceuticals plcLTM Sep 202662.7M +3.0%-0.8%
GHRSGH Research PLCLTM Mar 202662.03M +15.9%+5.5%
SUPNSupernus Pharmaceuticals, Inc.LTM Jun 202657.36M +3.1%+1.7%
ZVRAZevra Therapeutics, Inc.LTM Mar 202656.11M +13.7%+17.1%
MPLTMapLight Therapeutics, Inc.LTM Mar 202643.04M +3.9%+2.0%
ANROAlto Neuroscience, Inc.LTM Mar 202629.75M +10.2%+4.1%
PRAXPraxis Precision Medicines, Inc.LTM Sep 202627.42M +29.8%+94.2%
Peer median (excluding ZVRA) 62.36M+4.0%+2.2%

Competitors are the stored peer set for ZVRA. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue28.65M10.16M27.46M23.61M106.47M
Cost of Revenue2.06M222K2.95M7.42M16.48M
Gross Profit26.59M9.94M24.52M16.2M89.99M
Gross Margin92.8%97.8%89.3%68.6%84.5%
Research & Development10.16M19.8M39.81M42.1M12.74M
Selling, General & Admin8.7M15.04M35.09M54.87M77.62M
Operating Expenses18.86M52.5M74.12M103.2M94.22M
Depreciation & Amortization257K944K1.01M6.39M4.05M
EBITDA(7.89M)(25.53M)(43.54M)(76.4M)98.71M
EBITDA Margin-27.5%-251.2%-158.6%-323.6%92.7%
Operating Income7.73M(42.57M)(49.6M)(87M)(4.23M)
Operating Margin27.0%-418.9%-180.6%-368.5%-4.0%
Interest Income261K1.51M4.54M2.18M6.95M
Interest Expense376K335K1.5M7.35M7.98M
Other Income / Expenses(16.25M)15.76M3.56M(3.14M)90.91M
Income Before Tax(8.52M)(26.81M)(46.05M)(90.14M)86.68M
Pre-Tax Margin-29.7%-263.8%-167.7%-381.8%81.4%
Income Tax Expense34K(33K)015.37M3.45M
Net Income(8.56M)(26.77M)(46.05M)(105.51M)83.23M
Net Margin-29.9%-263.5%-167.7%-446.9%78.2%
EPS (Basic)(2.11)(0.78)(1.30)(2.28)1.40
EPS (Diluted)(2.11)(0.78)(1.30)(2.28)1.35
Weighted Avg Shares29.77M34.49M35.45M46.25M55.31M
Weighted Avg Shares (Diluted)29.77M34.49M35.45M46.25M57.26M

Zevra Therapeutics, Inc.

NASDAQ:ZVRA

Intrinsic Alpha fair value

Locked

Current Price

$9.28

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.